MGNX - MacroGenics' Lorigerlimab Shows Promise In Metastatic Prostate Cancer Treatment

Summary

• MacroGenics is a biopharmaceutical company focusing on cancer and autoimmune disorder treatment development with a broad pipeline of product candidates based on proprietary Fc optimization and Dual-Affinity Re-Targeting technology.
• Lorigerlimab is a bispecific, tetravalent, Fc-bearing (IgG4), PD-1 × CTLA-4 DART molecule being developed by MacroGenics for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
• A study on heavily pretreated mCRPC patients (n=42) using lorigerlimab showed a 25.7% cPR rate (4.6 month median duration) and 9 patients had PSA reductions of ? 90%.
• The safety profile of lorigerlimab appears to be similar to other cancer immunotherapies. Although a high proportion of patients experienced AEs, the majority were manageable and not life-threatening.
• Lorigerlimab positions MacroGenics firmly in the mCRPC market, but investors may not fully appreciate this until later-stage trials demonstrate its benefits. For now, holding onto MacroGenics may be advisable.

For further details see: